StockData
Medtronic plc logo

Medtronic plc (MDT) KPIs and segments

MDTNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends April 24
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 3, 2026Score 18/303% above fair value
$100.72−1.60 (-1.56%)

Close on Nov 18, 2026Market cap $128.83BP/E 24.7Yield 2.82%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Medtronic · năm tài chính kết thúc Last Friday of April (52/53-week fiscal year; FY2026 ended April 24, 2026; Q1 FY2027 14-week quarter ended July 31, 2026)

Nhìn nhanh KPI của Medtronic: 54 chỉ số vận hành, trong đó có Worldwide New Insulin Pumps Sold, Global CGM Sensor Attachment Rate và Diabetes Net Sales by Product Category, lấy từ 152 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Năm tài chính của Medtronic kết thúc Last Friday of April (52/53-week fiscal year; FY2026 ended April 24, 2026; Q1 FY2027 14-week quarter ended July 31, 2026) — Q1 FY27 = CQ2 2026 (quý dương lịch).

Periods

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q1 FY27
Q4 FY26
Q3 FY26
Q2 FY26
Q1 FY26
Q4 FY25
Q3 FY25
Q2 FY25
Q1 FY25
Q4 FY24
Q3 FY24
Q2 FY24
Reportable segment net sales($M)2
8,8846,6628,9858,9267,7856,1418,2608,3667,9676,0448,0357,923
United States($M)
4,6493,9144,4754,4943,9883,6084,2234,2864,0643,4654,1004,151
International($M)
4,2362,7484,5104,4323,7972,5334,0384,0803,9034,2153,9353,772
Cardiovascular($M)4
3,9273,7973,4573,4363,2853,3363,0373,1023,0073,1292,9292,923
International($M)
2,0742,0221,8681,8441,8061,7731,6321,6681,6041,6821,5561,496
United States($M)
1,8531,7751,5891,5921,4791,5621,4051,4341,4031,4481,3731,427
Non-U.S. Developed Markets($M)
1,039950912
Emerging Markets($M)
643607584
Neuroscience($M)4
2,6782,7512,5582,5622,4272,6202,4582,4512,3172,5452,3552,288
United States($M)
1,8131,8121,7091,7301,6241,7821,6891,6771,5651,6911,5561,560
International($M)
864938849832803838769774752853799728
Non-U.S. Developed Markets($M)
482442310
Emerging Markets($M)
37135784
Medical Surgical($M)4
2,2792,3872,1732,1712,0732,2112,0722,1281,9962,1982,1122,103
International($M)
1,2971,3661,2441,2281,1881,2661,1801,1831,1151,2441,1641,155
United States($M)
9821,022929943884946893944881954947948
Non-U.S. Developed Markets($M)
779758399
Emerging Markets($M)
396429329
Other Operating Segments, Including Diabetes($M)
872755
Diabetes($M)4
843838796757721728694686647659640610
International($M)
603599548527504488457455432436416394
United States($M)
240239248230217240236232215223224217
Non-U.S. Developed Markets($M)
337322740
Emerging Markets($M)
9994438
Other Operating Segments($M)2
32353331323738575361
United States($M)
172118222017151818262023
International($M)
121314131415171919323437
Other operating segment, misc($M)
2933
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)1
United States($M)
4,9064,8694,4934,5164,2244,5474,2374,3044,0824,3434,1204,175
International($M)
4,8504,9384,5244,4454,3544,3794,0554,0993,8324,2473,9683,809
Rest of world($M)
4,8104,9004,4884,4104,3214,3504,0274,0703,8034,2193,9423,780
Ireland($M)
403936353330282930272729
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2
Cardiovascular($M)
1,0331,068899877828955828781780-2201,0901,117
Neuroscience($M)
793879737740713858762725687-31994929
Medical Surgical($M)
485605499531486575512525459-139812795
Other Operating Segments, Including Diabetes($M)
7437
Diabetes($M)
57532638350332490118101
Other Operating Segments($M)
-1911131213
Kỳ báo cáo trước đây (báo cáo lần cuối 2025)1
Cardiovascular($M)
2,6192,5282,2982,3022,1532,2132,0732,0522,009
Neuroscience($M)
1,8921,9081,7431,7901,7031,8321,7461,7121,660
Medical Surgical($M)
1,3601,4231,3061,3401,2611,3411,2841,3091,218
Diabetes($M)
464441417455410398375
Medical Surgical($M)
31,90532,53532,74832,98433,32633,31733,586
Neuroscience($M)
19,94218,51418,44718,47918,43318,47618,270
Cardiovascular($M)
17,51717,55316,74816,66316,57316,54816,128
Other Operating Segments, Including Diabetes($M)
4,8274,433
Other Operating Segments($M)
4,7474,827207216202296547
Diabetes($M)
4,3124,2714,2094,1363,996
Remaining performance obligations (RPO)($M)
400400300400400400400500500
Worldwide New Insulin Pumps Sold (thousands of units)(M)
34.441.93932.131.94336.933.931.5
Global CGM Sensor Attachment Rate (%)(%)
69.0%68.0%67.0%65.0%64.0%63.0%61.0%59.0%57.0%
Diabetes Net Sales by Product Category ($M)($M)4
843837790752723724687682623
CGM Sensors & Transmitters Revenue ($M)($M)
431420390383360345330334304
Infusion Sets & Reservoirs (Pump Consumables) Revenue ($M)($M)
261249244234229223213210209
Durable Insulin Pumps Hardware Revenue ($M)($M)
144146151131119154136128123
Smart Pens & Other Diabetes Products Revenue ($M)($M)
7225415289-13
Diabetes Portfolio (Consolidated Segment) — Worldwide Revenue ($M)($M)7
843837796757721728694686647660640610
Medtronic Consolidated — Worldwide Revenue ($M)($M)8
9,7569,8079,0178,9618,5788,9278,2928,4037,9158,5898,0897,984
Consolidated Gross Margin Pricing Realization Benefit YoY (bps)(bps)
3030303030
Medtronic Consolidated — Organic Revenue Growth YoY (%)(%)
13.7%6.6%6.0%5.5%4.8%5.4%4.1%5.0%5.3%5.4%4.6%5.0%
Medtronic Consolidated — Foreign Currency Impact ($M)($M)
57308243111162-96-10445-93-756885
Medtronic Consolidated — Reported Revenue Growth YoY (%)(%)
13.7%9.9%8.7%6.6%8.4%3.9%2.5%5.3%2.8%0.5%4.7%5.3%
Medtronic Consolidated — U.S. Revenue ($M)($M)1
4,9064,8694,4934,5164,2244,5474,2374,3044,0824,3434,1204,175
Medtronic Consolidated — International Revenue ($M)($M)2
4,8504,9384,5244,4454,3544,3804,0554,0993,8324,2463,9683,809
Medtronic Consolidated — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
2,6742,4732,368
Medtronic Consolidated — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
1,5721,4951,441
Cardiovascular Portfolio — Worldwide Revenue ($M)($M)9
3,9273,7973,4573,4363,2853,3363,0373,1023,0073,1302,9292,923
Cardiac Ablation Solutions (CAS / PFA) — Global Organic Growth YoY (%)(%)2
88.0%78.0%80.0%71.0%
Cardiac Ablation Solutions (CAS) — U.S. Organic Growth YoY (%)(%)
139.0%124.0%137.0%
Cardiac Ablation Solutions (CAS) — U.S. Market Share Gain YoY (percentage points)(%)
9.0%8.0%4.0%
Cardiac Rhythm Management (CRM) — Global Organic Growth YoY (%)(%)
15.0%5.0%5.0%5.0%3.0%
Cardiovascular Portfolio — Organic Revenue Growth YoY (%)(%)
18.9%10.1%10.6%9.3%7.0%7.8%5.0%5.6%6.9%4.0%5.1%4.8%
Cardiovascular Portfolio — Foreign Currency Impact ($M)($M)
21124994668-37-3816-39-282831
Cardiovascular Portfolio — Reported Revenue Growth YoY (%)(%)
19.5%13.8%13.8%10.8%9.3%6.6%3.7%6.1%5.5%-5.2%6.1%5.9%
Cardiovascular Portfolio — U.S. Revenue ($M)($M)1
1,8531,7751,5891,5921,4791,5631,4051,4341,4031,4481,3731,427
Cardiovascular Portfolio — International Revenue ($M)($M)2
2,0742,0231,8681,8441,8061,7731,6321,6681,6041,6821,5561,496
Cardiovascular Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
1,039950912
Cardiovascular Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
643607584
Cardiac Rhythm & Heart Failure (CRHF — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5
2,1101,8561,8251,7121,7331,5451,5781,5351,5871,4701,492
Structural Heart & Aortic (SHA — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5
1,002929956930944874881856883843819
Coronary & Peripheral Vascular (CPV — Legacy through FY2026Q4) — Worldwide Revenue ($M)($M)5
685672655643659618643616660616613
Neuroscience Portfolio — Worldwide Revenue ($M)($M)7
2,6782,7512,5582,5622,4272,6202,4582,4512,3172,5452,3552,288
Neuroscience Portfolio — Organic Revenue Growth YoY (%)(%)
9.3%3.0%2.5%3.9%3.1%3.7%5.2%6.7%5.3%6.5%4.3%4.2%
Neuroscience Portfolio — Foreign Currency Impact ($M)($M)
652381527-18-2110-18-211010
Neuroscience Portfolio — Reported Revenue Growth YoY (%)(%)
10.3%5.0%4.1%4.5%4.3%2.9%4.4%7.1%4.4%5.6%4.8%4.7%
Neuroscience Portfolio — U.S. Revenue ($M)($M)1
1,8131,8121,7091,7301,6241,7821,6891,6771,5651,6921,5561,560
Neuroscience Portfolio — International Revenue ($M)($M)2
864938849832803838769774752853799728
Neuroscience Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
482442399
Neuroscience Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
371357329
Cranial & Spinal Technologies (CST) — Worldwide Revenue ($M)($M)6
1,3651,4031,3101,2991,2111,3421,2501,2341,1471,2911,2041,157
Core Spine Hardware — Global Organic Revenue Growth YoY (%)(%)
14.0%6.0%8.0%8.0%
Cranial & Spinal Technologies (CST) — Organic Revenue Growth YoY (%)(%)
12.9%3.3%3.7%4.7%4.5%4.4%4.6%6.4%4.8%8.7%6.5%6.7%
Cranial & Spinal Technologies (CST) — Foreign Currency Impact ($M)($M)
-21813612-7-93-9-1134
Cranial & Spinal Technologies (CST) — Reported Revenue Growth YoY (%)(%)
12.8%4.6%4.8%5.2%5.5%3.9%3.8%6.7%4.0%7.8%6.7%7.0%
Cranial & Spinal Technologies (CST) — U.S. Revenue ($M)($M)1
1,0161,031977966890999943926855936875863
Cranial & Spinal Technologies (CST) — International Revenue ($M)($M)2
349372333332320343307308292356329293
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M)($M)5
774806746744702759732737713778726705
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Organic Revenue Growth YoY (%)(%)
7.4%3.4%-0.2%0.3%-2.7%-1.6%1.9%3.9%3.4%3.1%3.4%2.6%
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Foreign Currency Impact ($M)($M)
6211559-7-85-7-931
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Reported Revenue Growth YoY (%)(%)
10.2%6.2%1.9%0.9%-1.5%-2.5%0.8%4.6%2.5%2.0%3.9%2.8%
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Revenue ($M)($M)
447431402409393431419418398439407403
Specialty Therapies (Neurovascular, ENT & Pelvic Health) — International Revenue ($M)($M)2
326374343335309328313319314339319302
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Worldwide Revenue ($M)($M)5
539542503520514520476480457475425426
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Organic Revenue Growth YoY (%)(%)
3.3%1.7%3.6%7.3%8.6%10.2%12.9%12.1%9.6%6.0%0.2%0.5%
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Foreign Currency Impact ($M)($M)
2131057-4-42-3-145
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — Reported Revenue Growth YoY (%)(%)
4.7%4.3%5.8%8.3%10.2%9.3%12.0%12.6%8.9%5.8%1.2%1.7%
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — U.S. Revenue ($M)($M)1
350350330355341352327333312317275293
Neuromodulation (Pain Stim, Brain Modulation & Drug Pumps) — International Revenue ($M)($M)2
189191173165174167149146146158150133
Medical Surgical Portfolio — Worldwide Revenue ($M)($M)7
2,2792,3882,1732,1712,0732,2122,0722,1281,9962,1982,1122,103
Medical Surgical Portfolio — Organic Revenue Growth YoY (%)(%)
10.2%5.1%2.7%1.3%2.4%2.0%-0.4%0.7%1.0%4.5%2.9%5.6%
Medical Surgical Portfolio — Foreign Currency Impact ($M)($M)
1581612740-30-3210-29-222027
Medical Surgical Portfolio — Reported Revenue Growth YoY (%)(%)
10.0%8.0%4.9%2.1%4.4%0.6%-1.9%1.2%-0.4%3.5%3.9%7.0%
Medical Surgical Portfolio — U.S. Revenue ($M)($M)1
9821,021929943884946893944881954947948
Medical Surgical Portfolio — International Revenue ($M)($M)2
1,2971,3661,2441,2281,1881,2661,1801,1831,1151,2441,1641,155
Medical Surgical Portfolio — Non-U.S. Developed Markets Revenue (Legacy through FY2024Q4, $M)($M)1
805758740
Medical Surgical Portfolio — Emerging Markets Revenue (Legacy through FY2024Q4, $M)($M)1
439429438
Surgical & Endoscopy — Worldwide Revenue ($M)($M)5
1,7401,8201,6541,6791,6011,7091,5961,6491,5441,7051,6161,641
Surgical & Endoscopy — Organic Revenue Growth YoY (%)(%)
9.0%3.5%1.4%1.1%2.3%1.7%0.4%1.3%5.0%3.4%6.8%
Surgical & Endoscopy — Foreign Currency Impact ($M)($M)
1469512332-25-269-22-151825
Surgical & Endoscopy — Reported Revenue Growth YoY (%)(%)
8.7%6.5%3.6%1.8%4.4%0.2%-1.2%0.5%-0.1%4.1%4.5%8.5%
Surgical & Endoscopy — U.S. Revenue ($M)($M)1
671694634665622668623675630679663688
Surgical & Endoscopy — International Revenue ($M)($M)2
1,0701,1261,0201,0149801,0419739749151,026953953
Acute Care & Monitoring — Worldwide Revenue ($M)($M)5
539568519493471503476478452492495462
Acute Care & Monitoring — Organic Revenue Growth YoY (%)(%)
14.2%10.5%7.0%2.0%2.6%3.1%-2.8%3.3%-0.1%2.5%
Acute Care & Monitoring — Foreign Currency Impact ($M)($M)
1121048-5-51-6-6
Acute Care & Monitoring — Reported Revenue Growth YoY (%)(%)
14.4%12.9%9.1%3.0%4.3%2.1%-3.9%3.6%-1.5%1.2%
Acute Care & Monitoring — U.S. Revenue ($M)($M)1
311328295278263278269269251275284260
Acute Care & Monitoring — International Revenue ($M)($M)2
228240224214209225206209200217211202
Cardiovascular — Segment R&D Expense ($M)($M)4
303273284299280259248256257
Cardiovascular — Segment SG&A Expense ($M)($M)
1,2691,1881,1291,1431,0601,0121,0101,021978
Cardiovascular — Segment Depreciation Expense ($M)($M)
716766566458565655
Cardiovascular — Segment Other Operating Expense ($M)($M)
14-1-14-17-15-14-14-7-6
Cardiovascular — Segment Goodwill Balance ($M)($M)
8,5838,6028,0378,0288,0458,0177,9297,9707,9777,9667,9067,849
Neuroscience — Segment R&D Expense ($M)($M)4
163139153167157149152158153
Neuroscience — Segment SG&A Expense ($M)($M)
922875841874831813820834808
Neuroscience — Segment Depreciation Expense ($M)($M)
788580797772737165
Neuroscience — Segment Other Operating Expense ($M)($M)
131312921212-411
Neuroscience — Segment Goodwill Balance ($M)($M)
12,67311,77711,75711,73811,75411,71611,61111,66811,65411,64411,67411,634
Medical Surgical — Segment R&D Expense ($M)($M)4
189163174181169169164171162
Medical Surgical — Segment SG&A Expense ($M)($M)
681650628627605593605609591
Medical Surgical — Segment Depreciation Expense ($M)($M)
655662535453515149
Medical Surgical — Segment Other Operating Expense ($M)($M)
556214455
Medical Surgical — Segment Goodwill Balance ($M)($M)
19,67519,95319,84219,78819,95219,74819,02519,26819,19819,12119,32519,084
Corporate & Shared Functions — Depreciation Expense ($M)($M)
696868616462575753
Remaining Performance Obligations / Contracted Backlog ($M)($M)3
400400400300400300400400400500500500
Deferred Revenue / Customer Contract Liabilities ($M)($M)1
500500468451442446462467461453447435
Revenue Recognized from Opening Contract Liability Balance ($M)($M)
140858594135695588108505892
Collaborative Arrangement Revenue ($M)($M)
123436373648504638
Allowance for Credit Losses on Accounts Receivable ($M)($M)
203190207200204199204195170173180177
Inventories by Production Stage — Total ($M)($M)3
6,2155,9516,3096,1565,8865,4765,6105,4795,4145,2175,7265,754
Finished Goods Inventory ($M)($M)
4,1214,0754,1944,1954,0223,7793,7403,7293,7323,6683,7993,775
Work in Process (WIP) Inventory ($M)($M)
900800883853792744782728696642788833
Raw Materials & Supplies Inventory ($M)($M)
1,1941,0761,2321,1081,0729531,0891,0229869071,1391,147
Intangible Asset Amortization Expense ($M)($M)9
412436441463459557416413414400419425
Quarterly Share Repurchases — Total Shares Purchased (millions)(M)3
2.774.510.923.301.392.911.932.8830.319.51.602.34
Stock-Based Compensation Expense by Award Type ($M)($M)5
1259595182868998159839085146
Unrecognized Tax Benefits (UTB) Balance ($M)($M)2
2,9003,0002,9002,9002,9002,9022,9002,9002,8002,8242,8002,800
Non-GAAP Operating Profit ($M)($M)10
2,3162,5002,1772,1622,0162,4862,1692,0411,9532,3112,0422,009
MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M)($M)19
843837790752723724687682623
MiniMed — Organic Revenue Growth YoY (%)(%)
15.8%8.7%8.6%7.8%
MiniMed — U.S. Net Sales ($M)($M)
240238242224212234231227211
MiniMed — International Net Sales ($M)($M)
603599548527511489456455412
MiniMed — Adjusted Standalone EBITDA ($M)($M)
83154127117851181078768
MiniMed — Adjusted EBITDA ($M)($M)
83-168978508373
MiniMed — Adjusted Gross Profit ($M)($M)
471487457434409411401
MiniMed — Adjusted Standalone Operating Income ($M)($M)
-68-5374486066479
MiniMed — Adjusted Standalone Net Income ($M)($M)
-53-4459384853377
MiniMed — GAAP Gross Profit ($M)($M)
465480362428409405395386342
MiniMed — GAAP R&D Expense ($M)($M)
11599114111125107112112105
MiniMed — GAAP SG&A Expense ($M)($M)
312299309293283276268271265
MiniMed — GAAP Operating Income / (Loss) ($M)($M)
5-91-10016-13-148217-27
MiniMed — GAAP Net Income / (Loss) ($M)($M)
0-183-111-5-16-168-7-5-19
MiniMed — Standalone Inventories ($M)($M)3
356341408311
MiniMed — Finished Goods Inventory ($M)($M)
193179199185
MiniMed — Work in Process Inventory ($M)($M)
35344438
MiniMed — Raw Materials Inventory ($M)($M)
12812816487
MiniMed — Standalone Remaining Performance Obligations ($M)($M)
463923
MiniMed — Standalone Contract Liabilities ($M)($M)
19191715
MiniMed — Customer Refund & Return Liabilities ($M)($M)
42454851
MiniMed — Property, Plant & Equipment, Net ($M)($M)
736711701706
MiniMed — Goodwill ($M)($M)
2,3002,3002,3002,300
FDA 510(k) Premarket Clearances — Medtronic1
91212893767738
FDA 510(k) Premarket Clearances — U.S. Industry Total
889835736823882767812814793750780941
FDA Premarket Approvals (PMA & Supplements) — Medtronic1
1141689313514712915995120132147139
FDA Premarket Approvals (PMA & Supplements) — U.S. Industry Total
616641434613597564607569575486582600
FDA Medical Device Recall Events — Medtronic1
281810661812114291614
FDA Device Enforcement Reports — Medtronic
23171067181111438238
FDA MAUDE Adverse Event Reports — Medtronic Total4
97,049104,15184,369101,86581,65966,22874,53967,79869,11064,20470,94973,691
ClinicalTrials.gov Newly Started Studies — Medtronic
12141115917108591210
Cardiovascular — Segment Revenue ($M, DB)($M)1
3,9273,7973,4573,4363,2853,3363,0373,1023,0073,1292,9292,923
Neuroscience — Segment Revenue ($M, DB)($M)1
2,6782,7512,5582,5622,4272,6202,4582,4512,3172,5452,3552,288
Medical Surgical — Segment Revenue ($M, DB)($M)1
2,2792,3872,1732,1712,0732,2112,0722,1281,9962,1982,1122,103
Consolidated Net Sales / Revenue ($M, DB)($M)9
9,7569,8079,0178,9618,5788,9278,2928,4037,9158,5898,0897,984
Total Assets ($M, DB)($M)8
93,30693,02891,48591,34690,97291,68089,97390,04289,74989,98190,83690,087
Operating Cash Flow ($M, DB)($M)3
1,7932,5732,7449251,0882,5282,5729589862,7772,474661

41 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Operational & Franchise KPIs (Groups 1–2): Diabetes hardware unit volume (Worldwide New Pumps Sold in thousands), Global CGM Attachment Rate (%), recurring sensor/consumable vs. pump hardware revenue mix, Consolidated Gross Margin Pricing Benefit (bps), flagship franchise organic growth (Cardiac Ablation Solutions / PFA, Cardiac Rhythm Management, Core Spine), and all active + legacy Operating Divisions across Worldwide, U.S., and International markets.
  • Cardiovascular Q1 FY2027 Reorganization & Legacy Geography (Step 5): In Q1 FY2027 (14-week quarter ended July 31, 2026), Medtronic reorganized Cardiovascular from 3 divisions (CRHF, SHA, CPV) into 4 divisions (EP Therapies, IC Therapies, CV Surgery, PV Health) without Q2–Q4 FY2026 restated quarters yet; the 3 legacy divisions are retained through FY2026Q4 while the 4 new divisions (<3 consecutive quarters) are listed in excluded. Similarly, Non-U.S. Developed & Emerging Markets revenue/organic growth are retained as legacy rows through FY2024Q4 alongside International division tables (FY2024Q1–FY2027Q1).
  • Consolidated − Standalone Assessment (Step 3 & Step 4): Medtronic plc files consolidated financial statements in Form 10-K/10-Q without SEC Schedule I parent-only financial statements; in its Irish Statutory Reports, parent Medtronic plc is a pure holding company (zero operating turnover). Therefore consolidated − parent subtraction is not applicable. Instead, listed subsidiary MiniMed Group, Inc. (Nasdaq: MMED, CIK 0002062583 — IPO March 2026, split-off completed Oct 19, 2026) and Medtronic Limited (UK Co. 01070807) are tracked directly from their self-reported filings in Group 6.
  • Period Splitting (Step 4): Only YTD subtraction (YTD − prior YTD and FY − 9M / Q4 = full year − nine months) is used where 10-K/10-Q/8-K report cumulative year-to-date cash flows or segment/XBRL totals. Zero self-computed ratios, margins, YoY rates, or sums exist anywhere in output/kpis.json.

Không hiện vì thiếu các kỳ gần đây (88)

  • MiniMed Worldwide Installed Pump Users (~659,000 users) — Disclosed only for a single period (FY2026) as '~659K' / 'more than 650,000' (bound / <3 periods); excluded per Step 5.
  • Annual Patients Served Worldwide ('78M+', '79M+', '82M+') — Disclosed only with '+' lower-bound qualifier in Earnings Presentations and Letters; excluded per Step 5 bound rule.
  • Cardiac Ablation Solutions FY2026Q1 Global Growth ('nearly 50%') & U.S. Growth ('over 70%') — Qualified as bounds in Q1 FY26; series starts at FY2026Q2 where exact point figures (71%, 80%, 78%, 88%) are published.
  • Organizational Health Survey Employee Response Rate ('more than 88%' in FY2025 vs. 87% in FY2026) — FY2025 disclosed only as bound ('more than 88%'), leaving <2 consecutive point years.
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Electrophysiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Interventional Cardiology Therapies (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Cardiovascular Surgery (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Reported Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — U.S. Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Foreign Currency Impact ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — International Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Cardiovascular Portfolio — Worldwide Revenue ($M) › Peripheral Vascular Health (New Q1 FY27 Division) — Worldwide Revenue ($M)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — Worldwide Revenue ($M) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Revenue ($M) › Specialty Therapies (Neurovascular, ENT & Pelvic Health) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Surgical Innovations (Legacy through FY2023Q4) — Worldwide Revenue ($M) › Surgical Innovations (Legacy through FY2023Q4) — U.S. Revenue ($M) › Surgical Innovations (Legacy through FY2023Q4) — U.S. Organic Revenue Growth YoY (%)
  • Operating Divisions, Therapy Franchises & Commercial Pricing (8-K / 10-Q / CFO Commentary) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — Worldwide Revenue ($M) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Revenue ($M) › Respiratory, Gastrointestinal & Renal (Legacy through FY2023Q4) — U.S. Organic Revenue Growth YoY (%)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment SG&A Expense ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Depreciation Expense ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Other Operating Expense ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M) › Diabetes — Segment Goodwill Balance ($M)
  • Portfolio R&D, SG&A, Depreciation & Goodwill (ASU 2023-07 Non-DB XBRL) › Diabetes — Segment R&D Expense ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › Customer Rebates Provision Balance ($M) › U.S. GAAP Rebate Liability Offset Against Accounts Receivable ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › Customer Rebates Provision Balance ($M) › U.S. GAAP Rebate Liability in Other Accrued Expenses ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Statutory Provisions for Liabilities — Total ($M) › MCS Product Exit Provision (FY2022–FY2023, $M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Manufacturing & R&D Equipment ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Computer Software & Enterprise Systems ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Buildings & Leasehold Improvements ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Construction in Progress — Capacity Expansion ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M) › Land & Land Improvements ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Gross Property, Plant & Equipment by Asset Class ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Operating Lease Cash Payments ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › ROU Assets Obtained in Exchange for New Operating Leases ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Operating Lease Weighted-Average Discount Rate (%)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Undiscounted Lease Commitments — Year +1 ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M) › Undiscounted Lease Commitments — Thereafter (>5 Years, $M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Operating Lease Cost ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Deferred Tax Assets Valuation Allowance ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › U.S. Defined Benefit Pension Projected Benefit Obligation ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › U.S. Defined Benefit Pension Fair Value of Plan Assets ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Non-U.S. Defined Benefit Pension Projected Benefit Obligation ($M)
  • Contract Backlog (RPO), Rebate/Warranty Reserves, Asset Stages & Non-GAAP Bridges › Unrecognized Tax Benefits (UTB) Balance ($M) › Non-U.S. Defined Benefit Pension Fair Value of Plan Assets ($M)
  • Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD) › Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) › Product Innovation Vitality Index — Revenue from Products Released in Prior 36M (%)
  • Global Workforce, Manufacturing Space, Compensation & Sustainability (DEF 14A / Irish Statutory / 10-K / Form SD) › Scope 1 & 2 GHG Emissions Intensity Reduction vs. FY2020 Baseline (%) › Aggregate Product Complaint Rate Reduction vs. FY2020 Baseline (%)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — U.S. Net Sales ($M) › MiniMed — U.S. Organic Growth (%)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — International Net Sales ($M) › MiniMed — International Organic Growth (%)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — Operating Cash Flow ($M)
  • Subsidiaries Self-Reported Filings (MiniMed Group, Inc. & Medtronic Limited UK) › MiniMed Group, Inc. (Nasdaq: MMED) — Standalone Net Sales ($M) › MiniMed — Capital Expenditures ($M)
  • External MedTech Regulatory, Clinical, Federal Procurement & Sector Benchmarks › U.S. PPI: Surgical & Medical Instrument Manufacturing (Index) › U.S. Hospitals Quarterly Revenue — Census QSS ($M)
  • Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Cost of Revenue ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Operating Income ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Diabetes — Segment Revenue ($M, DB) › Diabetes — Segment Total Assets ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Other Operating Segments — Revenue ($M, DB) › Other Operating Segments — Operating Income ($M, DB)
  • Reportable Segments & Geographic Context (Database) › Other Operating Segments — Revenue ($M, DB)
  • Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › United States — Long-Lived Assets ($M, DB)
  • Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › Ireland — Long-Lived Assets ($M, DB)
  • Reportable Segments & Geographic Context (Database) › United States — Geographic Revenue ($M, DB) › Other Countries ex-U.S. & Ireland — Long-Lived Assets ($M, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Gross Profit ($M, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › GAAP Diluted EPS ($, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Weighted-Average Diluted Shares (millions, DB)
  • Consolidated Financial Statements Context (Database) › Consolidated Net Sales / Revenue ($M, DB) › Cash Dividends Declared per Ordinary Share ($, DB)
  • Consolidated Financial Statements Context (Database) › Operating Cash Flow ($M, DB) › Acquisitions, Net of Cash Acquired ($M, DB)

Dữ liệu cập nhật 2026-10-31.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Medtronic

See a number that looks wrong?